71144-36-0

Usage

InChI:InChI=1/C7H5FO3/c8-5-2-7(11)6(10)1-4(5)3-9/h1-3,10-11H

Upstream product

• 71924-62-4 2-fluoro-4,5-dimethoxybenzaldehyde 

Downstream Products

• 71924-67-9 4,5-bis(benzyloxy)-2-fluorobenzaldehyde 
• 141523-16-2 4-Benzyloxy-2-fluoro-5-hydroxybenzaldehyde 
• 288856-38-2 2-fluoro-4,5-bis-(tetrahydro-pyran-2-yloxy)-benzaldehyde 
• 79418-76-1 6-fluoro-3-hydroxy-4-methoxybenzaldehyde 
• 166742-00-3 3-cyclopentyloxy-6-fluoro-4-methoxybenzaldehyde 
• 775350-82-8 (4-chloro-phenyl)-(5-cyclopentyloxy-2-fluoro-4-methoxy-phenyl)-methanol 
• 443955-87-1 7-fluoro-2,3-dihydro-benzo[1,4]dioxine-6-carbaldehyde 
• 945244-45-1 1-(6-fluorobenzo[1,3]dioxol-5-yl)cyclopropanecarboxylic acid 
• 743430-90-2 (6-bromo-2,3-dimethoxybenzyl)-[2-(6-fluorobenzo[1,3]dioxol-5-yl)ethyl]amine 
• 743430-91-3 2-(6-fluorobenzo[1,3]dioxol-5-yl)ethylamine 

Relevant academic research and scientific papers

Cytoprotective effect of caffeic acid phenethyl ester (CAPE) and catechol ring-fluorinated CAPE derivatives against menadione-induced oxidative stress in human endothelial cells

Caffeic acid phenethyl ester (CAPE), a natural polyphenolic compound with many biological activities, has been shown to be protective against ischemia-reperfusion injury. We have synthesized six new catechol ring-fluorinated CAPE derivatives and evaluated

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

An approach to the asymmetric synthesis of 18F-labeled analog of l-threo-3,4-dihydroxyphenylserine (6-l-threo-[18F]FDOPS) - A new radiotracer for visualization of norepinephrine transporters by positron emission tomography

An asymmetric synthesis method has been suggested as a feasible approach for the preparation of fluorine-18-labeled (T 1/2 110 min) analog of l-threo-3,4-dihydroxyphenylserine, i.e., 6-l-threo-[18F]FDOPS ((2S,3R)-2-amino-3-(2-[1

INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to compounds which specifically inhibit bacterial DNA Gyrase and can be used for the treatment of respiratory tract infections.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Synthesis of a series of caffeic acid phenethyl amide (CAPA) fluorinated derivatives: Comparison of cytoprotective effects to caffeic acid phenethyl ester (CAPE)

A series of catechol ring-fluorinated derivatives of caffeic acid phenethyl amide (CAPA) were synthesized and screened for cytoprotective activity against H2O2 induced oxidative stress in human umbilical vein endothelial cells (HUVEC

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

INHIBITORS OF DNA REPAIR ENZYMES AND METHODS OF USE THEREOF

Compounds are disclosed that inhibit enzymes of the uracil base excision repair (UBER) pathway. Inhibitors of uracil DNA glycosylase, pUTPase and AP endonuclease I are disclosed. The compounds can comprise a uracil substrate fragment and a second binding

NOVEL BENZODIOXOLES

The present invention relates to compound of formula (I) Wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.